Cube Dx hybcell technology

MANAGEMENT

EXPERIENCED TEAM
COMPLEMENTARY SKILLS / EXPERIENCES

Working for a common goal - establishing hybcell technology as international diagnostics standard.

»HOMECOMPANY

CEO and CSO

CHRISTOPH RESCHREITER

Christoph Reschreiter founded Cube Dx together with Bernhard Ronacher, after successfully developing and introducing hybcell technology to central European markets. Altogether he has worked more than ten years for the diagnostics industry. Before his entrepreneurial endeavors he worked for the international B&R industry electronics group as the head of international customer projects department. During his time at B&R he spent one year in Seoul (Republic of Korea) as an executive manager to set-up the newly founded Korean subsidiary.

Christoph Reschreiter is CEO and responsible for sales and organisation.

BERNHARD RONACHER

Bernhard Ronacher is a molecular biologist, geneticist and biochemist. He had developed the basic idea of the hybcell and founded Anagnostics and Cube Dx. During the years 2000 to 2002 he headed the molecular diagnostics laboratory of Lambda GmbH. There he established the DNA array technology. 2001 the first Austrian biochip, ParoCheck, was filed for patent. Bernhard has now worked for over 15 years in the development of advanced diagnostics solutions.

Bernhard Ronacher is CSO and responsible for science and technology.

Meet us

Meet us next...

...at the European Students Conference (www.esc-berlin.com) in Berlin. Cube Dx presents its Integrated Sepsis Diagnostics during a focussed industry exhibition and seminar on 29th of September, 2016. Make sure to be there. If you want to meet, make an appointment using info@cubedx.com!

News Ticker

Latest News...

We believe that the simultaneous (and parallel) measurement and evaluation of a set of biomarkers could improve the quality of clinical decisions of sepsis treatment. At ANESTHESIOLOGY® 2015, organised by the American Society of Anesthesiologists, a first study dealing with the quality of prognosis for single inflammatory and kidney markers in comparison to a combination of two of these markers was presented. The study was carried out by the Clinics of the Ludwig-Maximilians-University, Munich in collaboration with Clinic Neuperlach of the Municipal Hospital Munich.

The authors conclude that a combination of an inflammatory and a kidney biomarker leads to a significantly better prognosis than the use of single biomarkers, and can therefore more readily identify patients that are most critically affected by the disease. The authors recommend the simultaneous measurement of biomarkers to stratify a patient’s risk to die or of suffering critical kidney failure.